IP Library Granted Patent US 11,197,929
Granted Patent B2
US 11,197,929 · App. 17/163,239 · Granted Dec 14, 2021

Multimeric IL-15-based molecules

Inventors: Hing C. Wong (Weston, FL); Warren Marcus (Miramar, FL); Bai Liu (Cooper City, FL); Wenxin Xu (Pembroke Pines, FL); Robert G. Newman (Miramar, FL); Karen Kage (Miramar, FL); Lijing You (Miramar, FL); Peter Rhode (Miami, FL); Patrick Soon-Shiong (Culver City, CA)
Assignees: NantCell, Inc.; Altor BioScience, LLC.
A61K39/3955A61K38/005A61K38/2086A61P31/18A61P35/00C07K14/5443C07K14/7155C07K16/1045C07K16/2803C07K16/2818C07K16/2827C07K16/36A61K38/17A61K2039/505C07K2317/60C07K2317/622C07K2319/035C07K2319/30C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,197,929
App. No.
17/163,239
Granted
Dec 14, 2021
Kind
B2
Abstract

The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Claims (12)

1. An isolated soluble fusion protein complex comprising at least two soluble proteins, wherein

a first soluble protein comprises an interleukin-15 (IL-15) polypeptide domain and a second soluble protein comprises a soluble IL-15 receptor alpha sushi-binding domain (IL-15RαSu) fused to an immunoglobulin Fc domain,

wherein one of the first or second soluble protein further comprises a binding domain substantially identical to SEQ ID NO:2 or SEQ ID NO:6, and

wherein the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein to form a soluble fusion protein complex.

2. The soluble fusion protein complex of claim 1 , wherein one of the first or second soluble protein further comprises a second binding domain that specifically binds to a disease antigen, immune checkpoint molecule, or immune signaling molecule.

3. The soluble fusion protein complex of claim 1 , wherein the IL-15 polypeptide is an IL-15 variant comprising an N72D mutation (IL-15N72D).

4. The soluble fusion protein complex of claim 1 , wherein the binding domain comprises an immunoglobulin light chain variable domain covalently linked to an immunoglobulin heavy chain variable domain by a polypeptide linker sequence.

5. The soluble fusion protein complex of claim 1 , wherein the binding domain specifically binds to one or more molecules comprising: programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), cluster of differentiation 33 (CD33), cluster of differentiation 47 (CD47), glucocorticoid-induced tumor necrosis factor receptor (TNFR) family related gene (GITR), lymphocyte function-associated antigen 1 (LFA-1), tissue factor (TF), delta-like protein 4 (DLL4), single strand DNA or T-cell immunoglobulin and mucin-binding domain containing-3 (Tim-3).

6. The soluble fusion protein complex of claim 1 , wherein the first soluble protein comprises the amino acid sequence set forth in one of SEQ ID NOs: 2, 6, 10, 18, 20, 24, 28, 32, or 38.

7. The soluble fusion protein complex of claim 1 , wherein the second soluble protein comprises the amino acid sequence set forth in one of SEQ ID NOs: 4, 8, 12, 14, 16, 22, 26, 30, 34, 36, 40, 42, 44, 46, 51, 52, 53, or 54.

8. An isolated soluble fusion protein comprising an IL-15 peptide domain fused to a binding domain substantially identical SEQ ID NO:2 or SEQ ID NO:6.

9. An isolated soluble fusion protein comprising IL-15RαSu fused to both: (a) an immunoglobulin Fc domain; and (b) a binding domain substantially identical to SEQ ID NO:2 or SEQ ID NO:6.

Assignments (5)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2022
From: NANTCELL INC.
To: ALTOR BIOSCIENCE, LLC.
Reel/Frame 058814/0428 →
MERGER Recorded Sep 23, 2021
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 057582/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2021
From: SOON-SHIONG, PATRICK
To: NANTCELL INC.
Reel/Frame 057710/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2021
From: WONG, HING C.; MARCUS, WARREN D.; LIU, BAI; NEWMAN, ROBERT G.; KAGE, KAREN; YOU, LIJING; RHODE, PETER; XU, WENXIN
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 057881/0427 →
Continuity (5)
Continuation 16752606 · Jan 24, 2020
Continuation 15789985 · Oct 21, 2017
Provisional Application 62513964 · Jun 1, 2017
Provisional Application 62411216 · Oct 21, 2016
Related Publication 20210196821A1 · Jul 1, 2021